Following are the day’s biggest winners and losers. Find out why shares of Bed Bath & Beyond and DaVita popped while ConAgra and MGM dropped!   Read More

Credit Suisse is out today with a "fat" report on obesity. Nearly 200 pages. But besides its size, the research also stands out as one of the most unique pieces of Wall Street analysis I've ever seen.    Read More

The Dow closed lower on Tuesday with stocks slipping on concerns about the economy after consumer confidence fell to a 16-year low. What's the "Word on the Street?"   Read More

The week began with a flashback to the credit crisis.  It ended with figures showing the fastest inflation in six months and the lowest consumer-sentiment reading in 28 years.  Along the way, as the stock market ebbed and flowed, CNBC guests assembled a collective portfolio that was heavy on technology, energy, and global exposure.   Read More

Why invest in the U.S. when your own country has better stocks?   Read More

First, last Friday, Novo Nordisk put out a press release saying preliminary data show its drug works better than Byetta. And then, yesterday an analyst downgraded the stock just ahead of the company's long anticipated release of long-term results on its once-a-week version of Byetta.    Read More

Amylin fell more than 8% Monday after data from an important diabetes meeting sparked concern about competition to the drug Byetta. How to trade?   Read More

Gary Anderson thinks investors should look beyond America's borders for their stock-market winnings.   Read More

We are covering the ADA meeting today and tomorrow because most of the major data came out over the weekend or is coming out later today. Or so we thought.    Read More

Despite at least a couple of analysts coming out with relatively bullish post-ASCO research notes on Pfizer's oncology drug pipeline, PFE shares have fallen to yet another new low intra-day and have crossed another threshold.   Read More